Post from Yahoo FinanceWhat an embarrassment, this company’s leadership.
They have greatly exaggerated their claims to investors in private for years. ALS deal - nothing.
PD deal - nothing.
Diagnostic bio marker deals - nothing.
Covid test deals - nothing.
Multiple partnering deals imminent with terms exchanged - nothing.
Aducanumab inflection point - nothing.
NASDAQ inflection point - nothing.
Agora Financial exposure lifted the share price to over $0.70 in 2018 but company management did not seem happy and “managed” the share price back to $.06 over the next couple of years.
And of course, every December, tax loss selling driving the share price down. No doubt this year end will be the same.
Again, what an embarrassment.